Unlike in breast or bladder cancer, the significant improvement in pathologic response in the PROTEUS trial did not translate to a similarly impressive benefit in metastasis-free survival. This disconnect suggests that eliminating tumor in the prostate specimen is not a reliable surrogate for long-term outcomes in this disease setting.

The CCTG PR21 trial revealed a paradox: while Lutetium achieved a much higher PSA response rate than docetaxel chemotherapy, overall survival was better for patients who received docetaxel first. This counter-intuitive finding complicates treatment sequencing and challenges the assumption that higher initial response equals better long-term outcomes.

A meta-analysis of six trials (Poseidon) found no overall survival benefit from adding long-course (24 months) hormone therapy to post-operative radiotherapy. It suggests that a shorter course of 4-6 months is adequate for most men, marking a significant shift towards treatment de-escalation to reduce long-term toxicity without compromising efficacy in this specific setting.

For patients with biochemically recurrent prostate cancer, the decision to treat hinges on PSA doubling time. A doubling time of over two years carries a low risk of metastasis, often warranting observation. Conversely, a doubling time under three months indicates a high risk of metastasis within three years, necessitating intervention.

The PROTEUS trial used ADT plus surgery as its control, not surgery alone. This design is controversial because many patients choose surgery specifically to avoid systemic therapies like ADT. This complicates the interpretation of results and reflects a disconnect from real-world patient motivations.

The NCI working group asserts that PSA doubling time, especially a rate under six months, remains the key indicator of high-risk biochemically recurrent (BCR) prostate cancer. This biological marker of aggressiveness is considered more prognostically significant than the presence of lesions on a highly sensitive PSMA PET scan.

Early neoadjuvant trials in the 1990s failed to show clinical benefit because they included many low-risk patients and used less potent hormonal therapies. The PROTEUS trial's success was built on learning from this history by strictly enrolling high-risk patients and using a powerful androgen receptor pathway inhibitor (ARPI).

Intensive treatments like ADT plus an ARPI can suppress a patient's PSA so effectively that it becomes an unreliable marker of disease status. Patients may show radiographic progression on scans even while their PSA remains low and they feel clinically well. This discordance necessitates periodic imaging to avoid missing actual disease progression.

The innovative Triple Switch trial treats all patients with a doublet therapy and then uses their PSA response at six months to guide further treatment. Patients whose PSA fails to reach a nadir are then randomized to receive docetaxel chemotherapy, testing a strategy of early intensification based on a real-time biological response rather than upfront risk stratification.